Change 5-day change 1-year change 3-year change Capi.($)
+1.12%-1.04% - - 16.15M
+3.18%+4.58%+74.78%+134.00% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+3.60%+6.38%-11.56%-11.20% 23.75B
+2.20%+3.88%+10.46%+422.99% 23.19B
+3.64%+8.34%+39.81%-5.88% 18.14B
+2.64%+6.89%+41.94%-29.06% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
+2.31%+3.33%+24.15%+187.51% 13.56B
+7.20%+13.33%+42.13% - 12.97B
Average +2.73%+6.94%+52.63%+142.98% 26.21B
Weighted average by Cap. +2.48%+6.60%+57.30%+134.91%
Logo Opexa Therapeutics Inc
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Employees
-